CD40 mutant expression and its clinical significance to prognosis in gastric cancer patients

World Journal of Surgical Oncology

Chang-Ping Wu¹  Mei Ji²  Jie-Min Zhao²  Jun Wu²  Hong-Bing Shi²  Xiao-Dong Li²  Wei-Qing Zhao² 

[1] Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu Province, People’s Republic of China;Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu Province, People’s Republic of China

关键词: Immunohistochemistry;    CD40 mutant;    Gastric cancer;   

Others  :  811234
DOI  :  10.1186/1477-7819-12-167

 received in 2014-03-19, accepted in 2014-05-06,  发布年份 2014

【 摘 要 】

Background

We aimed to detect CD40 mutant expression and evaluate its clinical significance in gastric cancer.

Methods

CD40 mutant expression in 78 cases of gastric cancer tissues, 10 cases of normal gastric tissues, and 10 cases of gastric adenoma tissues by immunohistochemical test. Survival analyses were also performed.

Results

The positive CD40 mutant rate in gastric cancer was 55.1% (43/78). No positive CD40 mutant staining was observed in the normal gastric tissue or the gastric adenoma. CD40 mutants expression was significantly correlated with invasive depth, lymph metastasis, and TNM stage (P <0.05). Cases with negative CD40 mutant expression had a significantly longer median survival time than those with positive CD40 mutant expression (40 vs. 14 months, P <0.05). A lower death risk in negative CD40 mutant cases was observed comparing with positive CD40 mutant cases.

Conclusions

Positive CD40 mutant expression suggests a poorer prognosis of gastric cancer cases.

【 授权许可】

   
2014 Zhao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003, 362:305-315.
• [2]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 2008, 2008(127):2893-2917.
• [3]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [4]Clark EA, Ledbetter JA: Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A 1986, 83:4494-4498.
• [5]van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17.
• [6]Schonbeck U, Libby P: The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58:4-43.
• [7]Hess S, Engelmann H: A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996, 183:159-167.
• [8]Qi CJ, Zheng L, Ma HB, Fei M, Qian KQ, Shen BR, Wu CP, Vihinen M, Zhang XG: A novel mutation in CD40 and its functional characterization. Hum Mutat 2009, 30:985-994.
• [9]Bajtai A, Hidvegi J: The role of gastric mucosal dysplasia in the development of gastric carcinoma. Pathol Oncol Res 1998, 4:297-300.
• [10]Lo SS, Wu CW, Chi CW, Li AF, Chen JH, Lui WY: High CD40 expression in gastric cancer associated with expanding type histology and liver metastasis. Hepatogastroenterol 2005, 52:1902-1904.
• [11]Li R, Chen W-C, Pang X-Q, Tian W-Y, Wang W-P, Zhang XG: CD40 signal expression in gastric cancer tissue and its correlation with prognosis of gastric cancer patients. Mol Biol Rep 2012, 39:8741-8747.
• [12]Choudhury JA, Russell CL, Randhawa S, Young LS, Adams DH, Afford SC: Differential induction of nuclear factor-κB and activator protein-1 activity after CD40 ligation is associated with primary human hepatocyte apoptosis or intrahepatic endothelial cell proliferation. Mol Biol Cell 2003, 14:1334-1345.